[Asia Economy Reporter Myungwhan Lee] Humasis announced on the 16th that it has signed a trust contract to acquire treasury shares worth 10 billion KRW to stabilize its stock price and enhance shareholder value.


The contract period is from today until September 16, 2022, and will be conducted through Korea Investment & Securities.


Choi Jung-hak, CEO of Humasis, stated, "This treasury share acquisition is not only to stabilize the company's stock price but also a part of our confidence in continuous growth potential," adding, "The company plans to further establish the foundation for sustainable growth by expanding investments in various point-of-care diagnostic fields such as molecular diagnostics, biochemical diagnostics, and remote diagnostics, as well as diversifying the diagnostic sector and strategically expanding the market."



Along with the treasury share acquisition trust contract, Humasis plans to continue its efforts to enhance shareholder-friendly policies and shareholder value by proposing a cash dividend agenda at the regular shareholders' meeting to be held this month.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing